Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | Chief Scientific Officer | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2036-05-21 | Direct | 85,558 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 85,558 · Balance 85,558 F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,086 Underlying: Common Stock · 600 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 600 | $3.31 | $1,987.98 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:11 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 600 | $0.06 | $36.00 |
DisclosureSEC source: 0001301120-25-000027 · wk-form4_1765487480.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 371,686 Underlying: Common Stock · 5,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 5,000 | $3.52 | $17,623.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · balance_after: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 5,000 | $0.06 | $300.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,686 Underlying: Common Stock · 1,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 1,500 | $3.91 | $5,857.80 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.9112. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:56 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 1,500 | $0.06 | $90.00 |
DisclosureSEC source: 0001301120-25-000025 · wk-form4_1764896157.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 5,965 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,186 Underlying: Common Stock · 5,965 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 5,965 | $3.90 | $23,264.10 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,965 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.91. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:21 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 5,965 | $0.06 | $357.90 |
DisclosureSEC source: 0001301120-25-000023 · wk-form4_1764195711.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 535 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,151 Underlying: Common Stock · 535 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 535 | $3.94 | $2,105.23 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $3.917. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:20 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 535 | $0.06 | $32.10 |
DisclosureSEC source: 0001628280-25-054059 · wk-form4_1764123603.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $3.75 | $24,401.65 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.71. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 18:47 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000021 · wk-form4_1763578063.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 391,186 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $4.10 | $26,650.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 17:38 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000019 · wk-form4_1762969093.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 3,398 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,686 Underlying: Common Stock · 3,398 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 3,398 | $4.24 | $14,407.52 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.225. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 21:40 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 3,398 | $0.06 | $203.88 |
DisclosureSEC source: 0001301120-25-000017 · wk-form4_1762465222.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 3,102 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,084 Underlying: Common Stock · 3,102 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 3,102 | $4.40 | $13,634.22 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $4.35. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 20:29 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 3,102 | $0.06 | $186.12 |
DisclosureSEC source: 0001301120-25-000015 · wk-form4_1762374573.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 5,551 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 404,186 Underlying: Common Stock · 5,551 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 5,551 | $4.96 | $27,541.29 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.9625 to $4.95. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 21:04 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 5,551 | $0.06 | $333.06 |
DisclosureSEC source: 0001301120-25-000013 · wk-form4_1761771847.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 949 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,737 Underlying: Common Stock · 949 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 949 | $5.19 | $4,921.23 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.10. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 17:22 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 949 | $0.06 | $56.94 |
DisclosureSEC source: 0001301120-25-000011 · wk-form4_1761672139.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 6,500 | $4.97 | $32,286.80 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.02 to $4.88. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 16:24 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-25-000009 · wk-form4_1761063888.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 4,326 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 417,186 Underlying: Common Stock · 4,326 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 4,326 | $5.20 | $22,495.20 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.18. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 17:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 4,326 | $0.06 | $259.56 |
DisclosureSEC source: 0001301120-25-000007 · wk-form4_1760462176.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 45,632 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,512 Underlying: Common Stock · 45,632 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 45,632 | $7.01 | $319,880.32 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $6.70. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 45,632 | $0.06 | $2,737.92 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,042 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,144 Underlying: Common Stock · 2,042 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,042 | $5.65 | $11,537.30 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $5.65. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 21:16 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 2,042 | $0.06 | $122.52 |
DisclosureSEC source: 0001301120-25-000005 · wk-form4_1756329396.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,077 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,186 Underlying: Common Stock · 2,077 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,077 | $5.10 | $10,592.70 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 2,077 | $0.06 | $124.62 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionStock Option (right to buy) · Derivative | 2,227 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,263 Underlying: Common Stock · 2,227 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | SaleCommon Stock | 2,227 | $5.25 | $11,691.75 |
DisclosureSEC source: 0001708599-25-000097 · wk-form4_1755724400.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.